Patent ID: 8518955

Claim:
A method for treating a disease, disorder, syndrome or condition associated with the inhibition of transient receptor potential vanilloid 3 (TPRV3) function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of the formula (I): wherein X is O or S; Y is CR 3 or N; ring A is phenyl or pyridine; at each occurrence, R, which may be the same or different, is selected from hydrogen, halogen, or —OR a ; R 1 is hydrogen, halogen or substituted or unsubstituted alkyl; R 3 is hydrogen or substituted or unsubstituted alkyl, or R 1 and R 3 together with the carbon atoms to which they were attached may form a fused phenyl ring; R 2 is phenyl or pyridine, each of which may be optionally mono- or polysubstituted with substituent(s) independently selected from the group consisting of halogen, hydroxyl, nitro, cyano, —COOH, —NR 4 R 5 , acyl, substituted or unsubstituted alkyl, alkenyl, alkoxy, cyanoalkoxy, haloalkyl, haloalkyloxy, cycloalkyl, cycloalkylalkyl, cycloalkylalkoxy, aryl, heterocyclic group or heteroaryl; at each occurrence, R a , which may be the same or different, is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkyl, alkoxyalkyl, aryl, heteroaryl, heterocyclic group, cycloalkylalkyl, arylalkyl, heteroarylalkyl, or heterocyclylalkyl; at each occurrence, R 4 and R 5 , which may be the same or different, are independently selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic group, or heterocyclylalkyl; and ‘n’ is an integer ranging from 0 to 5, inclusive; or a pharmaceutically acceptable salt thereof.